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Background
In resource constrained settings where prevention of
mother to child transmission of HIV-1 (PMTCT) pro-
grams are in place, the proportion of residual in utero
transmission (rIUT) versus peri partum transmission (PPT)
is unknown and the morbidity/mortality related, or not,
to MTC transmission of HIV-1, within the first 6 weeks of
life, poorly documented.
Main objective
To assess the feasibility and the contribution of the very
early diagnosis on Dried Blood Spot (DBS), conducted at
day 0–day 3 of age in improving the medical care of HIV-
1 exposed newborn within the first 6 weeks of life.
Methods
Very early diagnosis was explained and proposed, before
and/or after delivery, to HIV positive mothers delivering
at Calmette and hospitals and health centers supported by
Magna Children at Risk (NMCHC, Chey Chumneas Hos-
pital and 3 Municipality Health Centers). A first negative
HIV-DNA negative DBS at day 0–day 3 was followed up
by a second DBS at W6. HIV-DNA positive DBS at d0–d3,
or at week 6 were followed up by a venipuncture as soon
as possible for HIV-RNA quantification (Kit G2 ANRS)
and CD4 count.
Preliminary results
Heel prick blood specimens were spotted on DBS for 272
newborns (ratio M/F = 1.3) at d0–d3. HIV DNA was
detected in 3 of 272 babies (rIUT rate: 1.1%). One of them
died before week 6. The two others presenting detectable
HIV-1 RNA viral loads at week 6 (6.4 and 6.9 log10 copies/
ml with CD4 at 19% and 21%, respectively) started first
line ARV regimen and became HIV-1 RNA undetectable
after 10 and 4 months of treatment. Among the 269 HIV-
DNA negative newborn at d0–d3, 228 (84.5%) have been
already seen at week 6 for virological confirmation, 23 are
still waiting for the visit of the week 6, 14 were lost of fol-
low up and 4 died without any AIDS clinical symptoms.
226 of 228 DBS were confirmed HIV-DNA negative at
week 6 whereas 2 infants became HIV-DNA positive (PPT
rate: 0.8%). Both were confirmed HIV-RNA positive two
weeks later (5.8 and 6.2 log10 copies/ml with CD4 at 33%
and 26%, respectively) and will soon begin their ARV
treatment.
Discussion
The rIU and PP transmission rates were low in this study
(1.1% and 0.8% respectively). 5 new born were diagnosed
HIV infected. One died before W6, and 2 already started
ARV treatment. Further investigations are undergoing to
understand why 14 newborn were lost of follow up. These
preliminary results demonstrate the feasibility of a mini-
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mally invasive very early diagnosis, done shortly after
birth. The small amount of blood required, the ease of
collection, storage, and transport of samples, and the low
cost of the test make it ideal for HIV-1 testing of infants in
remote maternities in Cambodia.Page 2 of 2
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